Dupuytren’s contracture: the status and impact of collagenase Clostridium histolyticum treatment in Austria

  • Altziebler J
  • Hubmer M
  • Parvizi D
  • et al.
N/ACitations
Citations of this article
4Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Over many decades, the treatment of Dupuytren’s disease, a fibroproliferative disease of the hand, is the centre of various studies and publications. Surgical intervention has always been the method of choice, with fasciectomy being today’s state of the art. Nevertheless, researchers also focused on conservative non-operative treatment methods of which collagenase Clostridium histolyticum (CCH) turned out to be very promising. With the release of CCH under the name Xiapex in 2010, its use increased steadily. The aim of this work is to survey the current state of the treatment with CCH and the status of Xiapex treatment in Austria.

Cite

CITATION STYLE

APA

Altziebler, J., Hubmer, M., Parvizi, D., Spendel, S., Rab, M., & Kamolz, L.-P. (2017). Dupuytren’s contracture: the status and impact of collagenase Clostridium histolyticum treatment in Austria. Safety in Health, 3(1). https://doi.org/10.1186/s40886-017-0063-8

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free